Last week, $127 was resistance but that was not monthly option expiration.
Fast money said Goldman Saks wants a cheaper buyin... When Wall Street gets it wrong..?
Stock gaps higher then runs! Monday we will discuss earnings
Posted for over a month here
This Small-Cap Cancer Immunotherapy Developer Just Snagged Another Big Partner
Interest is starting to heat up in the cancer immunotherapy space, and small-cap biotech Peregrine Pharmaceuticals finds itself squarely at ground zero.
Motley FoolPharmaceuticals & Drug TrialsCancerCancer cellAstraZe
Be back at close
This song has been in my head for weeks.
I think AAPl goes higher but modestly unlike NFLX and GOOD this week.
Therefore the play with calls is before close on July 21. However, RENOIR about to join da VICNI's party
Robert Iannone, Head of Immuno-Oncology, Global Medicines Development, at AstraZeneca said, “We believe that combination therapy in immuno-oncology has the potential to be a novel and highly effective approach to treating cancer. Our partnership with Peregrine provides the opportunity to explore an exciting, novel combination that could deliver important clinical benefit to patients across a range of cancers.”
saw it go from $4 to .50 up to $16.75 then down to $1-..Reverse split. back down
a run from .80 to $5.50 three years ago.
What is my point..?
Anyone who has been here 17 years...had the chance multiple times to had make money